
Regulatory
Latest Content

Shorts










Podcasts
Videos
All News

EMD Serono partners with the U.S. government to enhance IVF access, offering significant discounts on fertility treatments for millions of women.

Hunter Smith, CFO of Rhythm Pharmaceuticals, emphasized that in rare disease biotech, financial leadership must evolve from strict cost control to strategic partnerships.

Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.

In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.

Biopharmaceutical funding surges as companies like Veradermics, Peptilogics, and BridGene advance innovative therapies through significant financing rounds.

Pharmaceutical companies enhance cancer and autoimmune disease treatments through strategic collaborations, advancing innovative therapies, and improving patient outcomes.

Q&A with Harry Totonis, CEO and chairman of ConnectiveRx, on embracing change and seeking better solutions amid today’s challenging playing field for patient access.

In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.

Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, obesity, and cardiovascular diseases.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

A Harvard Business School Healthcare Alumni Association Q&A with Jennifer McCollum, CEO of Catalyst.

Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term biotech priorities depends on partnering.

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.

Johnson & Johnson plans to separate its orthopaedics business, creating DePuy Synthes, to enhance focus, innovation, and value for stakeholders.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.